Monopar Therapeutics Inc Sustainability Reports
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics for cancer patients and treatments for Wilson disease. Its programs include novel radiopharmaceuticals for oncology imaging and therapy alongside investigational oral medications.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300QJFAI7L6YHKG83
FIGI: BBG00J7K8DB7
4 reports from 2021 to 2025
